Article

Jyoti D. Patel on the Progress of Immunotherapy in NSCLC

Author(s):

Jyoti D. Patel

Jyoti D. Patel, ASCO expert, associate professor, Northwestern University Feinberg School of Medicine, discusses the progress of immunotherapy as treatment for patients with non-small cell lung cancer.

Jyoti D. Patel, ASCO expert, associate professor, Northwestern University Feinberg School of Medicine, discusses the progress of immunotherapy as treatment for patients with non-small cell lung cancer (NSCLC). Patel is reporting on data presented at the 2015 annual meeting of the American Society of Clinical Oncology, a gathering of nearly 30,000 oncology professionals in Chicago.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of two doctors and text.
Image of man.
Image of thumbnail.
Patients can prepare personal overviews to help care teams connect with them as individuals, explained Michelle Kirschner in an interview with CURE.
Enhertu with Perjeta nearly doubled progression-free survival versus standard treatment in metastatic HER2-positive breast cancer, study shows.
Expanding on a New Way to Manage Polycythemia Vera Without Iron Deficiency
Image of woman.
Image of two people.
Image of doctor.
Image of woman.
Related Content
The U.S. FDA has approved treatment with Ibtrozi patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer.
June 11th 2025

FDA Approves Ibtrozi for ROS1+ Advanced Non-Small Cell Lung Cancer

Spencer Feldman
The U.S. FDA has approved treatment with Ibtrozi for patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer.
CURE Cancer Horizons logo
February 26th 2024

FDA Approvals from February 2024

Alex Biese Brielle Benyon
February brought in multiple FDA approvals in the oncology space. Here’s an overview of some of the most recent ones.
Image of lungs.
June 10th 2025

The LAURA Trial May Lead to a New Era of Care in Lung Cancer

Ryan Scott
Dr. Suresh Ramalingam discusses how Tagrisso has ushered in a new era of care for patients with advanced EGFR+ non-small cell lung cancer.
Guidelines for Childhood Neuroblastoma, FDA Decisions and More
February 12th 2024

Guidelines for Childhood Neuroblastoma, FDA Decisions and More

Alex Biese Brielle Benyon
Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews
image of lungs
June 8th 2025

Targeted Chemo Improves Survival in Early-Stage Lung Cancer

Jordyn Sava
Using a 14-gene test to guide chemotherapy significantly improved disease-free survival in patients with early nonsquamous lung cancer.
Image of lung.
June 6th 2025

MVdeltaC Earns Orphan Drug Status for Pleural Mesothelioma

Spencer Feldman
The FDA granted orphan drug designation to MVdeltaC, a measles virus-based immunotherapy, for pleural mesothelioma, supporting its future development.